Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Maximus Inc is a specialty business services business based in the US. Maximus shares (MMS) are listed on the NYSE and all prices are listed in US Dollars. Maximus employs 38,000 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $63.60 |
|---|---|
| 52-week range | $56.50 - $88.46 |
| 50-day moving average | $65.53 |
| 200-day moving average | $75.74 |
| Wall St. target price | $83.50 |
| PE ratio | 15.9 |
| Dividend yield | $1.12 (1.76%) |
| Earnings per share (TTM) | $4.00 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $63.6 from 2022-07-01
| 1 week (2022-06-29) | 2.23% |
|---|---|
| 1 month (2022-06-02) | -1.53% |
| 3 months (2022-04-04) | -14.33% |
| 6 months (2022-01-06) | -18.75% |
| 1 year (2021-07-06) | -26.52% |
|---|---|
| 2 years (2020-07-06) | -9.47% |
| 3 years (2019-07-05) | 73.93 |
| 5 years (2017-07-05) | 2.30% |
Valuing Maximus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Maximus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Maximus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Maximus shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Maximus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.0716. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Maximus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Maximus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $484.5 million.
The EBITDA is a measure of a Maximus's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $4.7 billion |
|---|---|
| Operating margin TTM | 8% |
| Gross profit TTM | $947 million |
| Return on assets TTM | 7.14% |
| Return on equity TTM | 17.1% |
| Profit margin | 5.34% |
| Book value | $25.23 |
| Market capitalisation | $3.9 billion |
TTM: trailing 12 months
Dividend payout ratio: 28.07% of net profits
Recently Maximus has paid out, on average, around 28.07% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.76% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Maximus shareholders could enjoy a 1.76% return on their shares, in the form of dividend payments. In Maximus's case, that would currently equate to about $1.12 per share.
While Maximus's payout ratio might seem fairly standard, it's worth remembering that Maximus may be investing much of the rest of its net profits in future growth.
Maximus's most recent dividend payout was on 30 May 2022. The latest dividend was paid out to all shareholders who bought their shares by 11 May 2022 (the "ex-dividend date").
Maximus's shares were split on a 2:1 basis on 30 June 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Maximus shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Maximus shares which in turn could have impacted Maximus's share price.
Over the last 12 months, Maximus's shares have ranged in value from as little as $56.5 up to $88.4614. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Maximus's is 0.7101. This would suggest that Maximus's shares are less volatile than average (for this exchange).
Maximus, Inc. provides business process services (BPS) to government health and human services programs. It operates through three segments: U. S. Services, U. S. Federal Services, and Outside the U.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
